KINAXO Enters Agreement with Bristol-Myers Squibb Company

13-Oct-2010 - Germany

KINAXO Biotechnologies GmbH announced that Bristol-Myers Squibb Company has chosen KINAXO to support several of its drug discovery programs. Under the terms of the agreement, KINAXO will apply its chemical proteomics technologies to deconvolute molecular targets of compounds currently undergoing discovery research at Bristol-Myers Squibb to enable more informed decisions at various stages of the drug discovery process, such as selecting the right compound for clinical development.

Dr Jutta Fritz, Head of Business Development at KINAXO commented: “We are very pleased to collaborate with Bristol-Myers Squibb, one of the most prestigious pharmaceutical companies in the world. We are looking forward to building a productive partnership with Bristol-Myers Squibb, and consider this move to be a major milestone in expanding our business in the United States.”

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance